
Risultati per 'Miltenyi':
Di seguito l'elenco dei risultati di ricerca trovati rilevanti per la keyword 'Miltenyi':
Risultati maggiormente rilevanti:


Miltenyi Biotec offers research- and clinical-grade products for sample preparation, cell separation, flow cytometry, and cell culture applications. | Deutschland


Miltenyi Biomedicine is a newly established biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bring cancer treatments and regenerative therapies to patients worldwide. Learn more about us.


Your full-service CDMO partner. Miltenyi Bioindustry supports all efforts, from pre-clinical to commercial scale, as a full-service provider for the development and manufacturing of lentiviral vectors (LVVs) and cell and gene therapy (CGT) products.We are active on a global scale and with 30 years of extensive know-how, we are helping to shape this rapidly growing arena.
Altri risultati:


Building on Miltenyi’s decades of experience, we are uniquely positioned to realize the great potential of the new cell and gene therapies and make them available to patients worldwide. Both Miltenyi Biomedicine and Miltenyi Biotec were founded and are privately owned by Stefan Miltenyi who is advancing cellular therapy since 1989.


Miltenyi Biotec is a global biotechnology company headquartered near Cologne in Bergisch Gladbach, Germany. The company is a provider of products and services that support scientists, clinical researchers, and physicians across basic research, translational research, and clinical applications. The company offers solutions [buzzword] covering ...


Miltenyi Bioindustry focuses on harnessing the power of lentiviral gene delivery and expression technology. With decades of experience and a scalable lentiviral vector (LVV) platform, Miltenyi Bioindustry (formerly known as Lentigen Technology Inc. and now a business unit of Miltenyi Biotec) provides critical material to enable CGT applications.


Come Miltenyi Biotec siamo attenti alle esigenze dei nostri stakeholder e lavoriamo proponendo un portfolio con più di 18mila prodotti. Per il prossimo anno, abbiamo in pipeline strumenti aggiornati e protocolli nuovi a supporto dello studio dei tumori solidi.